Novel coronavirus disease 2019 pharmacological treatments: A review

dc.contributor.authorSawaya, Tania
dc.contributor.authorHaddad, Nisrine
dc.contributor.authorZaraket, Hassan
dc.contributor.authorRizk, Nesrine A.
dc.contributor.departmentPharmacology and Toxicology
dc.contributor.departmentExperimental Pathology, Microbiology, and Immunology
dc.contributor.departmentInternal Medicine
dc.contributor.departmentPharmacy
dc.contributor.departmentDivision of Infectious Diseases
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:39:45Z
dc.date.available2025-01-24T11:39:45Z
dc.date.issued2020
dc.description.abstractThe COVID-19 pandemic has caused an extraordinary need and challenge to identify effective therapeutic options for prevention and treatment. In this review, we summarize the major findings in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral characteristics and the novel coronavirus disease 2019 (COVID-19) pathophysiology, clinical presentation and outcomes. We then proceed to explain the mechanisms of action, outcomes, and adverse events identified for the front-running pharmacological treatments currently being used and/or investigated namely Remdesivir, Chloroquine/Hydroxychloroquine, Lopinavir/Ritonavir, Tocilizumab, and convalescent plasma. © 2020, American University of Beirut. All rights reserved.
dc.identifier.eid2-s2.0-85090650723
dc.identifier.urihttp://hdl.handle.net/10938/29341
dc.language.isoen
dc.publisherAmerican University of Beirut
dc.relation.ispartofMiddle East Journal of Anesthesiology
dc.sourceScopus
dc.subjectClinical pharmacology
dc.subjectCoronavirus
dc.subjectPandemics
dc.titleNovel coronavirus disease 2019 pharmacological treatments: A review
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2020-3287.pdf
Size:
607.75 KB
Format:
Adobe Portable Document Format